Compare · AKLI vs DXCM
AKLI vs DXCM
Side-by-side comparison of Akili Inc. (AKLI) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKLI and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $33.10B.
- DXCM has hit the wire 6 times in the past 4 weeks while AKLI has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for AKLI).
- Company
- Akili Inc.
- DexCom Inc.
- Price
- $0.43-0.05%
- $86.05-1.93%
- Market cap
- -
- $33.10B
- 1M return
- -
- -2.13%
- 1Y return
- -
- +25.75%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2005
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest AKLI
- PureTech Health plc – Half-Year Report
- SEC Form 15-12G filed by Akili Inc.
- SEC Form EFFECT filed by Akili Inc.
- Amendment: SEC Form SC 13D/A filed by Akili Inc.
- SEC Form 4 filed by Large owner Puretech Health Plc
- SEC Form 4 filed by Large owner Palihapitiya Chamath
- Amendment: SEC Form SC 13D/A filed by Akili Inc.
- Amendment: SEC Form SC 13G/A filed by Akili Inc.
- SEC Form 4 filed by Large owner Temasek Holdings (Private) Ltd
- President & CEO Franklin Matthew returned 33,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer